• By ICR Secretariat
  • Posted Monday, August 1, 2022

After failed Alzheimer's launch, Biogen writes off the remaining value of its Aduhelm inventory

https://www.fiercepharma.com/pharma/biogen-files-233-million-aduhelm-write-wake-aduhelm-overhaul

Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO switch and much more.